Effects of altered hepatic lipid metabolism on regulation of hepatic iNOS

Clinical Lipidology

Volumn 10, Issue 2, 2015, Pages 167-175

  Stanimirovic, Julijana ^a   Obradovic, Milan ^a   Zafirovic, Sonja ^a   Resanovic, Ivana ^a   Bogdanovic, Nikola ^a   Gluvic, Zoran ^b   Mousa, Shaker A ^c   Isenovic, Esma R ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b Clinical Hospital Center Zemun   (Serbia)

^c ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

inducible nitric oxide synthase; inflammation; lipid; liver; metabolism; nitric oxide

Indexed keywords

FATTY ACID; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; INTERLEUKIN 1BETA; INTERLEUKIN 6; NITRIC OXIDE; PROTEIN KINASE B; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; DIMERIZATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME REGULATION; ENZYME STABILITY; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84928576652     PISSN: 17584299     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.15.8     Document Type: Article

References (90)

1. Leclercq IA, Farrell GC, Sempoux C, Dela Pena A, Horsmans Y. Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. J. Hepatol. 41(6), 926-934 (2004).
2. Day CP, James OF. Steatohepatitis: a tale of two "hits" Gastroenterology 114(4), 842-845 (1998).
3. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin. Liver Dis. 21(1), 27-41 (2001).
4. Taylor BS, Alarcon LH, Billiar TR. Inducible nitric oxide synthase in the liver. regulation and function. Biochemistry (Mosc) 63(7), 766-781 (1998).
5. Charbonneau A, Marette A. Inducible nitric oxide synthase induction underlies lipid-induced hepatic insulin resistance in mice. potential role of tyrosine nitration of insulin signaling proteins. Diabetes 59(4), 861-871 (2010).
6. Perreault M, Marette A. Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat. Med. 7(10), 1138-1143 (2001).
7. Angulo P, Lindor KD. Treatment of nonalcoholic fatty liver: present and emerging therapies. Semin. Liver Dis. 21(1), 81-88 (2001).
8. Michel T, Feron O. Nitric oxide synthases: which, where, how, and why J. Clin. Invest. 100(9), 2146-2152 (1997).
9. Kypreos KE, Zafirovic S, Petropoulou PI et al. Regulation of endothelial nitric oxide synthase and high-density lipoprotein quality by estradiol in cardiovascular pathology. J. Cardiovasc. Pharmacol. Ther. 19(3), 256-268 (2014).
10. Soskic SS, Dobutovic BD, Sudar EM et al. Regulation of inducible nitric oxide synthase (iNOS) and its potential role in insulin resistance, diabetes and heart failure. Open Cardiovasc. Med. J. 5, 153-163 (2011).
11. Isenovic E, Lapointe MC. Role of Ca(2+)-independent phospholipase A(2) in the regulation of inducible nitric oxide synthase in cardiac myocytes. Hypertension 35(1 Pt 2), 249-254 (2000).
12. Gluvic Z, Koricanac G, Lazic E et al. Nitric oxide and its role in pathophisiological conditions. Materia. Medica. 22, 23-30 (2006).
13. Kanner J, Harel S, Granit R. Nitric oxide as an antioxidant. Arch. Biochem. Biophys. 289(1), 130-136 (1991).
14. Kim YM, Bergonia H, Lancaster JR Jr. Nitrogen oxide-induced autoprotection in isolated rat hepatocytes. FEBS Lett. 374(2), 228-232 (1995).
15. Harbrecht BG, Billiar TR, Stadler J et al. Inhibition of nitric oxide synthesis during endotoxemia promotes intrahepatic thrombosis and an oxygen radical-mediated hepatic injury. J. Leukoc. Biol. 52(4), 390-394 (1992).
16. Harbrecht BG, Stadler J, Demetris AJ, Simmons RL, Billiar TR. Nitric oxide and prostaglandins interact to prevent hepatic damage during murine endotoxemia. Am. J. Physiol. 266(6 Pt 1), G1004-G1010 (1994).
17. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite. implications for endothelial injury from nitric oxide and superoxide. Proc. Natl Acad. Sci. USA 87(4), 1620-1624 (1990).
18. Fujimoto M, Shimizu N, Kunii K et al. A role for iNOS in fasting hyperglycemia and impaired insulin signaling in the liver of obese diabetic mice. Diabetes 54(5), 1340-1348 (2005).
19. Merkel M, Eckel RH, Goldberg IJ. Lipoprotein lipase. genetics, lipid uptake, and regulation. J. Lipid Res. 43(12), 1997-2006 (2002).
20. Bechmann LP, Hannivoort RA, Gerken G et al. The interaction of hepatic lipid and glucose metabolism in liver diseases. J. Hepatol. 56(4), 952-964 (2012).
21. Knight BL, Hebbachi A, Hauton D et al. A role for PPARalpha in the control of SREBP activity and lipid synthesis in the liver. Biochem. J. 389(Pt 2), 413-421 (2005).
22. Schadinger SE, Bucher NL, Schreiber BM, Farmer SR. PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes. Am. J. Physiol. Endocrinol. Metab. 288(6), E1195-1205 (2005).
23. Shen LL, Liu H, Peng J et al. Effects of farnesoid X receptor on the expression of the fatty acid synthetase and hepatic lipase. Mol. Biol. Rep. 38(1), 553-559 (2011).
24. Banach M, Rizzo M, Obradovic M et al. PCSK9 inhibition-a novel mechanism to treat lipid disorders Curr. Pharm. Des. 19(21), 3869-3877 (2013).
25. Cohen DE. Balancing cholesterol synthesis and absorption in the gastrointestinal tract. J. Clin. Lipidol. 2(2), 004 (2008).
26. Kypreos KE, Zafirovic S, Petropoulou PI et al. Regulation of endothelial nitric oxide synthase and high-density lipoprotein quality by estradiol in cardiovascular pathology. J. Cardiovasc. Pharmacol. Ther. 19(3), 256-268 (2014).
27. Clemens M. NO in liver. In: The Liver Biology and Pathobiology. Arias I, Boyer J, Chisari F, Fausto N, Schachter D, Schafritz D (Eds). Lippincott Williams & Wilkins. Philadelphia, USA, 555-564 (2001).
28. Tache DE, Stanciulescu CE, Banita IM et al. Inducible nitric oxide synthase expression (iNOS) in chronic viral hepatitis and its correlation with liver fibrosis. Rom. J. Morphol. Embryol. 55(2 Suppl.), 539-543 (2014).
29. Dobutovic B, Sudar E, Tepavcevic S et al. Effects of ghrelin on protein expression of antioxidative enzymes and iNOS in the rat liver. Arch. Med. Sci. 10(4), 806-816 (2014).
30. Noronha BT, Li JM, Wheatcroft SB, Shah AM, Kearney MT. Inducible nitric oxide synthase has divergent effects on vascular and metabolic function in obesity. Diabetes 54(4), 1082-1089 (2005).
31. Schulz R, Rassaf T, Massion PB, Kelm M, Balligand JL. Recent advances in the understanding of the role of nitric oxide in cardiovascular homeostasis. Pharmacol. Ther. 108(3), 225-256 (2005).
32. Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem. J. 298(Pt 2), 249-258 (1994).
33. Hickey MJ, Granger DN, Kubes P. Inducible nitric oxide synthase (iNOS) and regulation of leucocyte/endothelial cell interactions. studies in iNOS-deficient mice. Acta Physiol. Scand. 173(1), 119-126 (2001).
34. Mungrue IN, Gros R, You X et al. Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J. Clin. Invest. 109(6), 735-743 (2002).
35. Parola M, Robino G. Oxidative stress-related molecules and liver fibrosis. J. Hepatol. 35(2), 297-306 (2001).
36. Geller DA, De Vera ME, Russell DA et al. A central role for IL-1 beta in the in vitro and in vivo regulation of hepatic inducible nitric oxide synthase. IL-1 beta induces hepatic nitric oxide synthesis. J. Immunol. 155(10), 4890-4898 (1995).
37. Ota T, Takamura T, Kurita S et al. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 132(1), 282-293 (2007).
38. Hsu W-H, Chen T-H, Lee B-H, Hsu Y-W, Pan T-M. Monascin and ankaflavin act as natural AMPK activators with PPAR agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice. Food. Chem. Toxicol. 64(0), 94-103 (2014).
39. Billiar TR, Curran RD, Stuehr DJ et al. An L-argininedependent mechanism mediates Kupffer cell inhibition of hepatocyte protein synthesis in vitro. J. Exp. Med. 169(4), 1467-1472 (1989).
40. Curran RD, Billiar TR, Stuehr DJ et al. Multiple cytokines are required to induce hepatocyte nitric oxide production and inhibit total protein synthesis. Ann. Surg. 212(4), 462-469; discussion 470-461 (1990).
41. Nussler AK, Di Silvio M, Billiar TR et al. Stimulation of the nitric oxide synthase pathway in human hepatocytes by cytokines and endotoxin. J. Exp. Med. 176(1), 261-264 (1992).
42. Boden G, She P, Mozzoli M et al. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver. Diabetes 54(12), 3458-3465 (2005).
43. Malhi H, Bronk SF, Werneburg NW, Gores GJ. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J. Biol. Chem. 281(17), 12093-12101 (2006).
44. Malhi H, Barreyro FJ, Isomoto H, Bronk SF, Gores GJ. Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut 56(8), 1124-1131 (2007).
45. Balligand JL, Cannon PJ. Nitric oxide synthases and cardiac muscle. Autocrine and paracrine influences. Arterioscler. Thromb. Vasc. Biol. 17(10), 1846-1858 (1997).
46. Billiar TR, Curran RD, Harbrecht BG et al. Modulation of nitrogen oxide synthesis in vivo. NG-monomethyl-L-arginine inhibits endotoxin-induced nitrate/nitrate biosynthesis while promoting hepatic damage. J. Leukoc. Biol. 48(6), 565-569 (1990).
47. Gaboury J, Woodman RC, Granger DN, Reinhardt P, Kubes P. Nitric oxide prevents leukocyte adherence. role of superoxide. Am. J. Physiol. 265(3 Pt 2), H862-H867 (1993).
48. Ferdinandy P, Schulz R. Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. Br. J. Pharmacol. 138(4), 532-543 (2003).
49. Nikolic D, Stanimirovic J, Bjelogrlic P, Isenovic E. Oxidative stress and the role of antioxidative treatment in diabetes mellitus. Oxid. Antioxid. Med. Sci. 3(1), 9-14 (2014).
50. Arthur MJ. Reactive oxygen intermediates and liver injury. J. Hepatol. 6(1), 125-131 (1988).
51. Szabo C, Southan GJ, Thiemermann C. Beneficial effects and improved survival in rodent models of septic shock with S-methylisothiourea sulfate, a potent and selective inhibitor of inducible nitric oxide synthase. Proc. Natl Acad. Sci. USA 91(26), 12472-12476 (1994).
52. Dallaire P, Bellmann K, Laplante M et al. Obese mice lacking inducible nitric oxide synthase are sensitized to the metabolic actions of peroxisome proliferator-activated receptor-gamma agonism. Diabetes 57(8), 1999-2011 (2008).
53. Boden G. Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver. Curr. Diab. Rep. 6(3), 177-181 (2006).
54. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336(15), 1066-1071 (1997).
55. Reddy JK, Rao MS. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am. J. Physiol. Gastrointest. Liver Physiol. 290(5), G852-G858 (2006).
56. Isenovic E, Soskic S, Dungen HD et al. Regulation of endothelial nitric oxide synthase in pathophysiological conditions. Cardiovasc. Hematol. Disord. Drug Targets (2011) (Epub ahead of print).
57. Sass G, Koerber K, Bang R, Guehring H, Tiegs G. Inducible nitric oxide synthase is critical for immune-mediated liver injury in mice. J. Clin. Invest. 107(4), 439-447 (2001).
58. Qatanani M, Lazar MA. Mechanisms of obesity-associated insulin resistance. many choices on the menu. Genes Dev. 21(12), 1443-1455 (2007).
59. Lara-Castro C, Garvey WT. Intracellular lipid accumulation in liver and muscle and the insulin resistance syndrome. Endocrinol. Metab. Clin. North Am. 37(4), 841-856 (2008).
60. Beaven SW, Matveyenko A, Wroblewski K et al. Reciprocal regulation of hepatic and adipose lipogenesis by liver X receptors in obesity and insulin resistance. Cell Metab. 18(1), 106-117 (2013).
61. Farese RV Jr, Zechner R, Newgard CB, Walther TC. The problem of establishing relationships between hepatic steatosis and hepatic insulin resistance. Cell Metab. 15(5), 570-573 (2012).
62. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease. old questions and new insights. Science 332(6037), 1519-1523 (2011).
63. Hooper AJ, Adams LA, Burnett JR. Genetic determinants of hepatic steatosis in man. J. Lipid Res. 52(4), 593-617 (2011).
64. Pilon G, Dallaire P, Marette A. Inhibition of inducible nitric-oxide synthase by activators of AMP-activated protein kinase. a new mechanism of action of insulin-sensitizing drugs. J. Biol. Chem. 279(20), 20767-20774 (2004).
65. Carvalho-Filho MA, Ueno M, Hirabara SM et al. S-nitrosation of the insulin receptor, insulin receptor substrate 1, and protein kinase B/Akt. a novel mechanism of insulin resistance. Diabetes 54(4), 959-967 (2005).
66. Kapur S, Bedard S, Marcotte B, Cote CH, Marette A. Expression of nitric oxide synthase in skeletal muscle: a novel role for nitric oxide as a modulator of insulin action. Diabetes 46(11), 1691-1700 (1997).
67. Yu C, Chen Y, Cline GW et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J. Biol. Chem. 277(52), 50230-50236 (2002).
68. Park E, Wong V, Guan X, Oprescu AI, Giacca A. Salicylate prevents hepatic insulin resistance caused by short-term elevation of free fatty acids in vivo. J. Endocrinol. 195(2), 323-331 (2007).
69. Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat. Rev. Immunol. 8(12), 923-934 (2008).
70. Obradovic M, Sudar E, Zafirovic S et al. Estradiol In vivo induces changes in cardiomyocytes size in obese rats. Angiology 66(1), 25-35 (2013).
71. Anai M, Funaki M, Ogihara T et al. Altered expression levels and impaired steps in the pathway to phosphatidylinositol 3-kinase activation via insulin receptor substrates 1 and 2 in Zucker fatty rats. Diabetes 47(1), 13-23 (1998).
72. Shimomura I, Matsuda M, Hammer RE et al. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol. Cell 6(1), 77-86 (2000).
73. Shinozaki S, Choi CS, Shimizu N et al. Liver-specific inducible nitric-oxide synthase expression is sufficient to cause hepatic insulin resistance and mild hyperglycemia in mice. J. Biol. Chem. 286(40), 34959-34975 (2011).
74. Li S, Brown MS, Goldstein JL. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc. Natl Acad. Sci. 107(8), 3441-3446 (2010).
75. Leavens KF, Easton RM, Shulman GI, Previs SF, Birnbaum MJ. Akt2 is required for hepatic lipid accumulation in models of insulin resistance. Cell Metab. 10(5), 405-418 (2009).
76. Schattenberg JM, Singh R, Wang Y et al. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology 43(1), 163-172 (2006).
77. Shimabukuro M, Ohneda M, Lee Y, Unger RH. Role of nitric oxide in obesity-induced beta cell disease. J. Clin. Invest. 100(2), 290-295 (1997).
78. Valenti L, Riso P, Mazzocchi A et al. Dietary anthocyanins as nutritional therapy for nonalcoholic fatty liver disease. Oxid. Med. Cell. Longev. 2013, 145421 (2013).
79. Hamaguchi M, Kojima T, Takeda N et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann. Intern. Med. 143(10), 722-728 (2005).
80. Hsiao PJ, Kuo KK, Shin SJ et al. Significant correlations between severe fatty liver and risk factors for metabolic syndrome. J. Gastroenterol. Hepatol. 22(12), 2118-2123 (2007).
81. Marchesini G, Brizi M, Bianchi G et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50(8), 1844-1850 (2001).
82. Bhat G, Baba CS, Pandey A, Kumari N, Choudhuri G. Insulin resistance and metabolic syndrome in nonobese Indian patients with non-alcoholic fatty liver disease. Trop. Gastroenterol. 34(1), 18-24 (2013).
83. Vonghia L, Michielsen P, Francque S. Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis. Int. J. Mol. Sci. 14(10), 19867-19890 (2013).
84. Asrih M, Jornayvaz FR. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. J. Endocrinol. 218(3), R25-R36 (2013).
85. Notarnicola M, Misciagna G, Tutino V et al. Increased serum levels of lipogenic enzymes in patients with severe liver steatosis. Lipids Health Dis. 11, 145 (2012).
86. Katan MB. The response of lipoproteins to dietary fat and cholesterol in lean and obese persons. Curr. Cardiol. Rep. 8(6), 446-451 (2006).
87. Flock MR, Green MH, Kris-Etherton PM. Effects of adiposity on plasma lipid response to reductions in dietary saturated fatty acids and cholesterol. Adv. Nutr. 2(3), 261-274 (2011).
88. Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia 13(1), 9-19 (2009).
89. Tietge UJ, Boker KH, Manns MP, Bahr MJ. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am. J. Physiol. Endocrinol. Metab. 287(1), E82-E89 (2004).
90. Li J, Billiar TR. Nitric Oxide. IV. Determinants of nitric oxide protection and toxicity in liver. Am. J. Physiol. 276(5 Pt 1), G1069-G1073 (1999).